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Abstract 
Alterations in the endothelial permeability occur in response to the activation of coagulation 
mechanisms in order to control clot formation. The activation of the protease activated 
receptors (PAR) can induce signals that regulate such cellular responses. PAR2 is a target 
for the coagulation factor Xa (fXa) and tissue factor-factor VIIa (TF-fVIIa) complex. By 
measuring the permeability of dextran blue across endothelial monolayer, we examined the 
mechanisms linking coagulation and endothelial permeability. Activation of PAR2 using the 
agonist peptide (PAR2-AP) resulted in increased permeability across the monolayer and was 
comparable to that obtained with VEGF at 60 min. Incubation of cells with activated factor Xa 
(fXa) resulted in an initial decrease in permeability by 30 min, but then significantly increased 
at 60 min. These responses required fXa activity, and were abrogated by incubation of the 
cells with a PAR2-blocking antibody (SAM11). Activation of PAR2 alone, or inhibition of 
PAR1, abrogated the initial reduction in permeability. Additionally, inclusion of Rivaroxaban 
(0.6 µg/ml) significantly inhibited the response to fXa. Finally, incubation of the endothelial 
monolayers up to 2 h with TF-containing microvesicles derived from MDA-MB-231 cells, in 
the presence or absence of fVIIa, did not influence the permeability across the monolayers. 
In conclusion, fXa but not TF-fVIIa is a noteworthy mediator of endothelial permeability. The 
rapid initial decrease in permeability requires PAR2 and PAR1 which may act to constrain 
bleeding. The longer-term response is mediated by PAR2 with increased permeability, 
presumably to enhance clot formation at the site of damage. 
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Introduction 
Under physiological conditions, the endothelial layer acts as one of the regulators of the 
haemostatic mechanism, acting as a barrier between the blood and the underlying 
thrombogenic tissue. However, this barrier is dynamic and is regulated to conform to the 
requirements of the local vasculature. Alterations in endothelial permeability are essential in 
the maintenance of the correct homeostatic functions but also, are often central in the 
pathogenesis of inflammatory and vascular disorders. Following injury, the responses by the 
vasculature limits blood flow and then allows seepage into the sub-endothelial layer. 
Protease activated receptors are G-protein coupled receptors which act as sensors for the 
presence of active proteases, in particular those that are involved in the coagulation 
mechanism [1,2]. The endothelial cells express PAR1 and PAR2 which mediate numerous 
outcomes that include changes to endothelial permeability [3-5]. PAR2 signalling is induced 
following the proteolysis by coagulation factor Xa (fXa), tissue factor-factor VIIa (TF-fVIIa) 
complex as well as by trypsin I, II and IV, tryptase, acrosin, granzyme A and kallikrein 2, 4, 6 
and 14, in a canonical manner, and by elastase, proteinase 3 and cathepsins G and S in a 
non-canonical system [6,7]. The activation of PAR2 has also been associated with 
inflammatory responses during chronic disorders [2,8] and suggested as a cause of vascular 
complications associated with various diseases [4,9]. 
Endothelial cells are connected to each other by a complex set of junction proteins [10-
13]. Under normal conditions, inter-endothelial junctions open to permit the passage of 
molecules and surveillance cells in a dynamic and size-selective manner [14-16]. Moreover, 
a number of inflammatory agents including thrombin and VEGF, are able to stretch out these 
junctions permitting contact between plasma and the sub-endothelial layer [17-19]. It has 
been shown that endothelial cells respond to coagulation by altering the vascular 
permeability [20]. However, little is known of the endothelial responses under conditions of 
coagulation, when the proteases are simultaneously generated. Furthermore, the overall 
response is likely to also be dependent on the magnitude of coagulation activation, which in 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 4 
turn would be dependent on the extent of the injury incurred. The role of PAR2 in the 
alteration of vascular permeability has not been defined. Current reports equally ascribe the 
activation of PAR2 signalling to increases in endothelial permeability [8,21,22], and refute 
such a response [23,24]. In addition, it has been suggested that PAR2 acts in conjunction 
with PAR1 to desensitize subsequent cellular responses to thrombin [5]. In this study we 
have examined the ability of fXa and TF-fVIIa to influence the permeability of endothelial 
monolayers. In addition, by inhibiting fXa activity and blocking PAR2 activation, the role of 
these proteins in the regulation of endothelial permeability is further clarified. 
 
Material and methods 
Cell culture and endothelial-barrier permeability assay 
Human coronary artery primary endothelial cells (HCAEC) and human dermal blood-
microvascular endothelial cells (HDBEC), devoid of endogenous TF were cultured in MV 
media containing 5% (v/v) foetal calf serum (FCS) and growth supplements (PromoCell, 
Heidelberg, Germany). MDA-MB-231 breast cancer cell line (ATCC, Teddington, UK) was 
cultured in DMEM, containing 10% (v/v) FCS.  
The in vitro endothelial barrier assay was adapted by modification of a previously 
described procedure [5]. Transwell polyester membrane inserts (3.0 µm pore size; Thermo 
Scientific, Warrington, UK) were coated with 0.5% (w/v) gelatin (Sigma Chemical Company 
Ltd, Poole, UK) and incubated for 2 h prior to usage. Cells (6×104) were seeded out and 
cultured in complete endothelial cell medium and propagated for 4 days to obtain confluent 
monolayers. The permeability of the monolayers was assessed under test conditions without 
any stimulus and found to remain uncompromised for >2 h. On the day of the experiments, 
the monolayers were washed twice with phosphate buffered saline (PBS). The cells were 
then incubated for 1 h in with equal volumes of serum-free endothelial medium at the upper 
and lower chambers. Blue dextran MW 4×104 (Sigma) was diluted to a final concentration of 
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1 µg/ml in PBS was then added to the upper chamber of each Transwell. Any test-chambers 
with apparent leakages at the start of the experiment were excluded. The test reagents were 
then added to the upper chambers and incubated at 37°C for up to 120 min. Aliquots of the 
media (200 µl) were removed from the bottom chamber and the absorption measured at 584 
nm. 
Preparation of test reagents 
Rivaroxaban was obtained as pure compounds from Bayer (Leverkusen, Germany), 
dissolved in dimethyl sulfoxide (DMSO) and diluted in PBS to 4 mg/ml working stock 
solutions. Appropriate controls using similarly diluted DMSO were used alongside, as 
controls. The final concentrations of the Rivaroxaban were optimised against purified fXa 
beforehand to ensure maximal inhibition. Vascular endothelial growth factor (VEGF)-A (TCS 
Cellworks/Caltag Medsystems Ltd, Buckingham, UK) was diluted to 25 ng/ml final 
concentration in the base culture medium. Protease activated receptor 2-agonist peptide 
(PAR2-AP; SLIGKV) and PAR1-AP (TFLLR) were synthesised (Severn Biotech Ltd, 
Kidderminster, UK) and used at a final concentration of 20 µM [25]. Coagulation factors Xa 
and VIIa (Enzyme Research Laboratories, Swansea, UK) were diluted stepwise to the 
required concentrations (10 nM and 5 nM) in the base culture medium. Recombinant TF 
(Innovin thromboplastin reagent; Dade Behring, Deerfield, USA) was used at a final 
concentration of 1 U/ml (1.3 ng/ml). Blocking antibodies for PAR2 (SAM11) and PAR1 
(ATAP2) were obtained from Santa Cruz Biotechnology (Heidelberg, Germany) and were 
incubated with the cells at 20 µg/ml to prevent the activation of PAR2 and PAR1 
respectively. 
Preparation and quantification of the TF-containing microvesicles 
MDA-MB-231 cells were propagated in 25 cm2 flasks. To generate the TF-containing 
microvesicles, the cells were washed and adapted to DMEM serum-free medium, for 2 h. 
The released microvesicles were then prepared from the conditioned media by 
ultracentrifugation according to described procedures [26]. The functional density of the 
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released of microvesicles was determined using the Zymuphen MP-assay kit (Hyphen 
BioMed/Quadratech, Epsom, UK) and the microvesicle density determined from the 
standards provided by the kit. The released microvesicle-associated TF antigen was 
measured using the Quantikine TF-ELISA kit (R&D Systems, Abingdon, UK) according to 
the manufacturer's instructions. Cell surface TF antigen was measured in situ using an 
ELISA-based procedure a previously described [27,28]. 
Chromogenic activity assays 
Thrombin generation potential of the purified microvesicles was confirmed using a two-
stage chromogenic thrombin generation assay as before [27]. The activity of fXa was 
measured using a chromogenic fXa substrate (0.2 mM; Hyphen). 
Statistical analysis 
All data represent the calculated mean values from the number of experiments stated in 
each figure legend ± the calculated standard error of the mean. Statistical analysis was 
carried out using the Statistical Package for the Social Sciences (SPSS Inc. Chicago, USA). 
Significance was determined using one-way ANOVA (analysis of variance) and Tukeys 
honesty significance test or where appropriate, by paired t-test. 
Results 
To ensure that the endothelial monolayers were not affected for the duration of the 
assay by the lack of serum, the presence of blue dextran or the inclusion of DMSO, initially 
the Transwell-monolayers were monitored over 2 h and confirmed to remain intact (not 
shown). Incubation of the monolayer without any stimulus resulted a gradual increase in the 
transfer of dextran blue as expected, but this was not significant over the period of analysis 
(Fig. 1) and therefore deemed to be a stable model. 
Activation of PAR2 by fXa alters the permeability across the endothelial monolayer 
The activation of both HCAEC and HDBEC using PAR2-AP resulted in increased 
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permeability within 60 min but was less than that induced by VEGF (Fig. 1). No further 
increase in the permeability was detected after this time point. Furthermore, incubation of 
cells with PAR1-AP did not result in any significant change in the permeability of endothelial 
monolayer which in agreement with some [5], but contradictory to other reports [24]. 
Incubation of HCAEC and HDBEC monolayers with fXa (10 nM) prevented the change in the 
permeability across the monolayers and therefore, resulted in a relative decrease when 
compared to the untreated sample at the same time point (Fig. 2). This was replaced by a 
significant increase in the leakage of blue dextran (80% and 92% increase) across HCAEC 
and HDBEC monolayers respectively, at 60 min post-addition of fXa. Incubation of 
endothelial monolayers with a lower concentration of fXa (5 nM) did not result in the initial 
reduction in permeability at 30 min and the ensuing increase in permeability was not 
significant. 
The induction of endothelial permeability requires fXa proteolytic activity 
Rivaroxaban is direct oral anticoagulant which function through binding and directly 
inhibiting fXa. To ensure complete inhibition of fXa, samples of fXa were pre-incubated with 
therapeutic and sub-therapeutic concentrations of Rivaroxaban (0.6 and 0.06 µg/ml) prior to 
measuring the residual fXa activity using a fXa-chromogenic substrate (Fig. 3). In order to 
examine the requirement for the proteolytic function of fXa, endothelial monolayers were 
incubated with fXa (10 nM) and also in the presence of Rivaroxaban (0.06 and 0.6 µg/ml). 
Inclusion of Rivaroxaban (0.6 µg/ml) significantly inhibited the response of the endothelial 
monolayer to fXa (92% inhibition) (Fig. 4A). Rivaroxaban also prevented the initial reduction 
in permeability at 30 min (Fig. 4B). 
The induction of endothelial permeability is mediated through PAR2 activation 
To determine if the observed changes in permeability were as a consequence of the 
proteolytic activation of PAR2 by fXa, sets of HCAEC and HDBEC were pre-incubated with 
blocking antibodies to PAR2 and PAR1. Inhibition of PAR2 using SAM11 antibody prior to 
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addition of fXa (10 nM) abrogated all changes in permeability of the monolayer in response 
to fXa (Fig. 5). Activation of cells with fXa in the presence of PAR1 blocking antibody 
(ATAP2) resulted in the omission of the initial reduction in permeability. However, the 
increase in permeability at 60 min was not significantly altered when compared to fXa alone. 
Factor Xa but not TF-fVIIa complex is capable of inducing endothelial permeability 
In addition to fXa, the TF-fVIIa complex is known to be capable of activating PAR2 
directly. Therefore, the possibility that TF-containing microvesicles may also be capable of 
increasing the endothelial permeability through PAR2 activation was explored. TF-containing 
microvesicles were isolated from MDA-MB-231 cells and confirmed to posses significant 
thrombin generation potential at 10 nM. Thereafter, endothelial monolayers were incubated 
with TF-containing microvesicles (10 nM final concentration), or alternatively with 
recombinant TF (1 U/ml), in the presence or absence of additional fVIIa (5 nM). Incubation of 
HCAEC for 60 or 120 min with TF-containing microvesicles, or recombinant TF was largely 
ineffective in increasing the permeability of the monolayers and remained unaltered on 
inclusion of fVIIa (Fig. 6A). Finally, the inclusion of both fXa and fVIIa with either the 
microvesicles or recombinant TF did not enhance the permeability of the endothelial 
monolayers, beyond that observed with fXa alone (Fig. 6B). 
 
Discussion 
The ability of the vasculature to determine the nature and magnitude of a stimulus is 
essential for the appropriate and proportionate response. The vascular response to injury 
include rapid changes to blood flow to reduce the loss of blood, followed by increased 
contact with the sub-endothelial layer, in order for the formation of a stable and effective clot 
[29-32]. In agreement with this hypothesis the incubation of the endothelial monolayers with 
fXa resulted in an initial reduction in permeability followed by significantly higher levels of 
leakage across to the lower chamber. Interestingly, incubation of endothelial monolayers 
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with sub-optimal levels of fXa (5 nM) did not produce any response while at 10 nM, the 
enzyme produced full response in the cells. The magnitude of increased permeability at 60 
min, following activation with fXa (10 nM) was higher than that obtained with PAR2-AP. 
Furthermore, the response to PAR2-AP did not produce the initial tightening of the 
endothelial layer at 30 min. Activation of fX within the blood is initiated by the TF-fVIIa 
complex and therefore the relatively lower amounts of fXa generated by the extrinsic 
pathway may be incapable of causing vascular permeability. Conversely, full activation of the 
coagulation involving the intrinsic pathway can convert a large quantity of the available fX at 
the locality of the injury. Therefore, it is plausible that under these conditions the adaptations 
in the permeability of the endothelial layer to allow contact between plasma and the sub-
endothelial layer, becomes an essential step in the completion and strengthening of the clot. 
This mechanism appears to be dependent on the proteolytic activity of fXa and was 
significantly diminished in the presence of Rivaroxaban. As stated above, while some 
studies report that the activation of PAR2 signalling promotes endothelial permeability 
[8,21,22], others did not find a response [23,24]. Furthermore, Feistritzer and Riewald [5] 
suggested that PAR1 and PAR2 act in conjunction to desensitize endothelial response to 
further activation. Our data indicate that the activation of PAR2 appears to be a major 
inducer of permeability and may participate in the original reduction endothelial tightness. A 
recent report has shown that the activation of PAR2 can disrupt cellular tight junctions 
through the activation of p38 MAPK alone [33]. However, concurrent activation of ERK1/2 
and Akt pathways in response to PAR2 activation may occur independently [33,34]. 
Furthermore, some PAR2 signalling appears to be dose dependent even when using the 
activating peptide [35]. These data are in accord with our finding that the induction of PAR2 
using the activating peptide results in the activation of p38 MAPK the magnitude of which 
can further be modulated by other factors including the presence of TF [36]. Moreover, the 
activation of PAR2 alone using the agonist peptide did not produce the initial tightening of 
the endothelial layer at 30 min. Consequently, PAR1 appears to be an essential contributor 
to the initial reduction in permeability. Therefore, the responses of PAR2, in conjunction with 
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PAR1 appear to constitute a means of converting the signal arising from fXa into the 
converse but canonical and time-dependent modifications in endothelial permeability. It has 
been recognised that while PAR2 constitutes the main receptor for fXa induced signalling, 
PAR1 also acts as a minor target for fXa [37] and may be involved in fXa signalling [38]. The 
protective influence of PAR1 [5,39.40] in thrombin-mediated signalling, on endothelial 
function has been documented [4,5]. Moreover, the ability of PAR1 to induce endothelial 
permeability is known [41]. However, thrombin appears to influence vascular permeability 
through multiple mechanisms including direct signalling, by influencing other cells through 
the nitric oxide-mediated pathways. Moreover, the outcomes of response to thrombin appear 
to be both cell-specific and target-selective, affecting various different proteins within the 
cellular tight junction [42]. In addition, some of the differences in the outcomes appears to 
arise from the requirement for cell-surface effectors such as APC or PAR3 [4,43] although 
some reports dispute a direct role for PAR3 in the response to PAR1 or the expression of 
PAR4 on some endothelial cells [44]. Finally, it has been suggested that the magnitude of 
activation of PAR1 is amplified by proteolytic action of thrombin, in comparison to for 
example by PAR1-activating peptide [45,46]. Therefore, we are not able to present a 
conclusive explanation for the lack of alterations in permeability in response to PAR1-
activating peptide. Additionally, the focus of our study has been the role of fXa as a first 
messenger in regulating the induction of endothelial permeably in response to the activation 
of coagulation. Consequently, the discussions on the multiple roles of thrombin and the 
magnitude of PAR1 activation, together with the multiple second messengers and pathways 
involved in PAR signalling [3,4] is beyond the scope of our study. Consequently, the 
outcome of PAR1 activation was not further pursued in this study. However, in addition to 
the contribution from PAR1, co-operative signalling from other receptors such as EPCR 
[53,54] may also contribute to PAR2 signalling and require clarification. 
The initial reduction and the subsequent increase in permeability proposes a regulatory 
process to control bleeding. However, following repeated injury, or during long-term 
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presence of the inflammatory stimuli, these mechanisms may become defective and even 
detrimental. The expression of TF is a hallmark of chronic inflammatory conditions but TF-
fVIIa complex is not always fully active and can exist in an encrypted or partially active 
format [47-52]. In our experiments, either recombinant TF, or TF contained within 
microvesicles derived from a cell line did not affect the endothelial permeability. Intriguingly, 
the inclusion of fVIIa with the TF also was not capable of eliciting similar responses to fXa. 
Previously we showed that TF-containing microvesicles from MDA-MB-231 cells begin to be 
assimilated within the endothelial cell membrane within 30 min of incubation [55]. To ensure 
sufficient intervals cell permeability was analysed at 60 and 120 min following induction. This 
finding suggest that the presence of TF per se is not sufficient to induce such alterations in 
permeability which in turn may escalate into thrombus formation [56,57]. Moreover, this 
observation questions the role of plasma seepage arising from endothelial permeability, as 
the main cause of distal thromboembolism, for example in cancer patients who have 
detectable amounts of circulating TF-containing microvesicles. However, the possibility of 
the involvement of a ternary complex TF-fVIIa-fXa is not dismissed and it is feasible that 
once sufficient fXa is generated by the coagulation mechanism, the induction of permeability 
may be enhanced by TF-fVIIa-fXa complex formation. Regardless, the use of anti-fXa agents 
such as direct oral anticoagulants may be effective in limiting the vascular permeability and 
oedema formation. 
The crosstalk between the coagulation mechanism and the vasculature ensures correct 
haemostasis following injury. Among the components involved in this communication is 
PAR2 which responds to generated proteases. This study indicates that the activation of 
PAR2 by the proteolytic action of fXa but not TF-fVIIa complex, mediates endothelial 
responses that initially result in the reduction of vascular permeability, and subsequently 
promote increased contact between blood plasma and the sub-endothelial layer. 
Authors' contributions 
The study was designed by AM, MC and CE, and the experimental work carried out by NB 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 12 
and SF. The data were evaluated by NB, AM, MJ and CE and the manuscript was prepared 
by NB and CE. 
Acknowledgements 
Rivaroxaban was provided by Bayer as pure compound and is acknowledged. 
References 
1. Nieman MT. Protease-activated receptors in hemostasis. Blood. 2016;128(2):169-177. 
doi: 10.1182/blood-2015-11-636472. 
2. Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin 
Immunopathol. 2012;34(1):133-149. doi: 10.1007/s00281-011-0289-1. 
3. McCoy KL, Traynelis SF, Hepler JR. PAR1 and PAR2 couple to overlapping and distinct 
sets of G proteins and linked signaling pathways to differentially regulate cell physiology. 
Mol Pharmacol. 2010;77(6):1005-1015. doi:10.1124/mol.109.062018. 
4. Alberelli MA, De Candia E. Functional role of protease activated receptors in vascular 
biology. Vascul Pharmacol. 2014;62(2):72-81. doi:10.1016/j.vph.2014.06.001. 
5. Feistritzer C, Lenta R, Riewald M. Protease-activated receptors-1 and -2 can mediate 
endothelial barrier protection: role in factor Xa signaling. J Thromb Haemost. 
2005;3(12):2798-2805. 
6. Zhao P, Metcalf M, Bunnett NW. Biased signaling of protease-activated receptors. Front 
Endocrinol (Lausanne). 2014;5:67. doi: 10.3389/fendo.2014.00067. 
7. Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP, Ramachandran R. 
Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory 
disease. Br J Pharmacol. 2014;171(5):1180-1194. doi: 10.1111/bph.12544. 
8. Vergnolle N, Hollenberg MD, Sharkey KA, Wallace JL. Characterization of the 
inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in 
the rat paw. Br J Pharmacol. 1999;127(5):1083-1090. 
9. Bucci M, Roviezzo F, Cirino G. Protease-activated receptor-2 (PAR2) in cardiovascular 
system. Vascul Pharmacol. 2005;43(4):247-253. 
10. Zhang R, Ge J. Proteinase-Activated Receptor-2 Modulates Ve-Cadherin Expression to 
Affect Human Vascular Endothelial Barrier Function. J Cell Biochem. 
2017;118(12):4587-4593. doi: 10.1002/jcb.26123. 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 13 
11. Van Itallie CM, Anderson JM. Architecture of tight junctions and principles of molecular 
composition. Semin Cell Dev Biol. 2014;36:157-165. doi: 10.1016/j.semcdb.2014.08.011. 
12. Claesson-Welsh L. Vascular permeability--the essentials. Ups J Med Sci. 
2015;120(3):135-143. doi: 10.3109/03009734.2015.1064501. 
13. Vestweber D. Relevance of endothelial junctions in leukocyte extravasation and vascular 
permeability. Ann N Y Acad Sci. 2012;1257:184-92. doi: 10.1111/j.1749-
6632.2012.06558.x. 
14. Sukriti S, Tauseef M, Yazbeck P, Mehta D. Mechanisms regulating endothelial 
permeability. Pulm Circ. 2014;4(4):535-551. doi: 10.1086/677356. 
15. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol 
Rev. 2006;86(1):279-367. 
16. Chavez A, Smith M, Mehta D. New insights into the regulation of vascular permeability. 
Int Rev Cell Mol Biol. 2011;290:205-248. doi: 10.1016/B978-0-12-386037-8.00001-6. 
17. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W. Vascular endothelial growth 
factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci. 
1998;111(Pt 13):1853-1865. 
18. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth 
factors. Vascul Pharmacol. 2002;39(4-5):225-237. 
19. Chidlow JH Jr, Sessa WC. Caveolae, caveolins, and cavins: complex control of cellular 
signalling and inflammation. Cardiovasc Res. 2010 1;86(2):2192-25. doi: 
10.1093/cvr/cvq075. 
20. Lupu C, Westmuckett AD, Peer G, Ivanciu L, Zhu H, Taylor FB Jr, Lupu F. Tissue factor-
dependent coagulation is preferentially up-regulated within arterial branching areas in a 
baboon model of Escherichia coli sepsis. Am J Pathol. 2005;167(4):1161-72. PubMed 
PMID: 16192650. 
21. Sawada S, Ono Y, Egashira Y, Takagi T, Tsuruma K, Shimazawa M, Iwama T, Hara H. 
In Models of Intracerebral Hemorrhage, Rivaroxaban is Superior to Warfarin to Limit 
Blood Brain Barrier Disruption and Hematoma Expansion. Curr Neurovasc Res. 
2017;14(2):96-103. doi: 10.2174/1567202613666161216150835. 
22. Kumar Vr S, Darisipudi MN, Steiger S, Devarapu SK, Tato M, Kukarni OP, Mulay SR, 
Thomasova D, Popper B, Demleitner J, Zuchtriegel G, Reichel C, Cohen CD, 
Lindenmeyer MT, Liapis H, Moll S, Reid E, Stitt AW, Schott B, Gruner S, Haap W, 
Ebeling M, Hartmann G, Anders HJ. Cathepsin S Cleavage of Protease-Activated 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 14 
Receptor-2 on Endothelial Cells Promotes Microvascular Diabetes Complications. J Am 
Soc Nephrol. 2016;27(6):1635-1649. doi: 10.1681/ASN.2015020208. 
23. Vouret-Craviari V, Grall D, Van Obberghen-Schilling E. Modulation of Rho GTPase 
activity in endothelial cells by selective proteinase-activated receptor (PAR) agonists. J 
Thromb Haemost. 2003;1(5):1103-1111. 
24. Klarenbach SW, Chipiuk A, Nelson RC, Hollenberg MD, Murray AG. Differential actions 
of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: 
the role of Rho-GTPases. Circ Res. 2003;92(3):272-278. 
25. Collier, MEW, Ettelaie, C. Regulation of the incorporation of tissue factor into 
microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J. 
Biol. Chem. 2011;286:11977-11984. doi: 10.1074/jbc.M110.195214. 
26. Ettelaie C, Collier ME, Maraveyas A, Ettelaie R. Characterization of physical properties 
of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based 
recovery procedures. Journal of Extracellular Vesicles 2014;3:23592. doi: 
10.3402/jev.v3.23592. 
27. Collier MEW, Ettelaie C, Goult BT, Maraveyas A, Goodall AH. Investigation of the 
Filamin A-Dependent Mechanisms of Tissue Factor Incorporation into Microvesicles. 
Thromb Haemost. 2017;117(11):2034-2044. doi: 10.1160/TH17-01-0009. 
28. Ettelaie C, Collier ME, Featherby S, Greenman J, Maraveyas A. Peptidyl-prolyl 
isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its 
release within microvesicles. Biochim Biophys Acta. 2017;1865(1):12-24. doi: 
10.1016/j.bbamcr.2017.09.016. 
29. Burnstock G, Ralevic V. New insights into the local regulation of blood flow by 
perivascular nerves and endothelium. Br J Plast Surg. 1994;47(8):527-543. 
30. Lucas C, Leys D. Vasodilation in spontaneous cervical artery dissection. Front Neurol 
Neurosci. 2005;20:64-69. 
31. Wu KK, Thiagarajan P. Role of endothelium in thrombosis and hemostasis. Annu Rev 
Med. 1996;47:315-331. 
32. Ehrlich HP, Trelstad RL, Fallon JT. Dermal vascular patterns in response to burn or 
freeze injury in rats. Exp Mol Pathol. 1981;34(3):281-289. 
33. Enjoji S, Ohama T, Sato K. Regulation of epithelial cell tight junctions by protease-
activated receptor 2. J Vet Med Sci. 2014;76(9):1225-1229. 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 15 
34. Jacob C, Yang PC, Darmoul D, Amadesi S, Saito T, Cottrell GS, Coelho AM, Singh P, 
Grady EF, Perdue M, Bunnett NW. Mast cell tryptase controls paracellular permeability 
of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem. 
2005;280(36):31936-31948. 
35. Cenac N, Chin AC, Garcia-Villar R, Salvador-Cartier C, Ferrier L, Vergnolle N, Buret AG, 
Fioramonti J, Bueno L. PAR2 activation alters colonic paracellular permeability in mice 
via IFN-gamma-dependent and -independent pathways. J Physiol. 2004;558(3):913-925. 
36. Ettelaie C, Elkeeb AM, Maraveyas A, Collier ME. p38α phosphorylates serine 258 within 
the cytoplasmic domain of tissue factor and prevents its incorporation into cell-derived 
microparticles. Biochim Biophys Acta. 2013;1833(3):613-621. doi: 
10.1016/j.bbamcr.2012.11.010. 
37. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of 
protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 
2000;97(10):5255-5260. 
38. Camerer E, Kataoka H, Kahn M, Lease K, Coughlin SR. Genetic evidence that protease-
activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem. 
2002;277(18):16081-16087. 
39. Sen P, Gopalakrishnan R, Kothari H, Keshava S, Clark CA, Esmon CT, Pendurthi UR, 
Rao LV. Factor VIIa bound to endothelial cell protein C receptor activates protease 
activated receptor-1 and mediates cell signaling and barrier protection. Blood. 
2011;117(11):3199-3208. doi: 10.1182/blood-2010-09-310706. 
40. Sundaram J, Keshava S, Gopalakrishnan R, Esmon CT, Pendurthi UR, Rao LV. Factor 
VIIa binding to endothelial cell protein C receptor protects vascular barrier integrity in 
vivo. J Thromb Haemost. 2014;12(5):690-700. 
41. Malik AB, Fenton JW 2nd. Thrombin-mediated increase in vascular 
endothelialpermeability. Semin Thromb Hemost. 1992;18(2):193-9. 
42. Kondo N, Ogawa M, Wada H, Nishikawa S. Thrombin induces rapid disassembly of 
claudin-5 from the tight junction of endothelial cells. Exp Cell Res. 2009;315(17):2879-
2887. doi: 10.1016/j.yexcr.2009.07.031. 
43. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell 
protease activated receptor 1 by the protein C pathway. Science. 2002;296(5574):1880-
1882. 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 16 
44. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF. 
Thrombin responses in human endothelial cells. Contributions from receptors other than 
PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem. 
2000;275(18):13502-13509. 
45. Liu LW, Vu TK, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling 
hirudin binds to thrombin and alters enzyme specificity. J Biol Chem. 
1991;266(26):16977-16980. 
46. Aschner JL, Lennon JM, Fenton JW 2nd, Aschner M, Malik AB. Enzymatic activity is 
necessary for thrombin-mediated increase in endothelial permeability. Am J Physiol. 
1990;259(4):L270-5.  
47. Kothari H, Pendurthi UR, Rao LV. Analysis of tissue factor expression in various cell 
model systems: cryptic vs. active. J Thromb Haemost. 2013;11(7):1353-1363. doi: 
10.1111/jth.12272. 
48. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol. 2006;26(3):456-461. 
49. Butenas S, Amblo-Krudysz J, Mann KG. Posttranslational modifications of tissue factor. 
Front Biosci (Elite Ed). 2012;4:381-391. 
50. Egorina EM, Sovershaev MA, Osterud B. Regulation of tissue factor procoagulant 
activity by post-translational modifications. Thromb Res. 2008;122(6):831-837. doi: 
10.1016/j.thromres.2007.11.004. 
51. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: 
ionophore treatment induces changes in tissue factor activity by phosphatidylserine-
dependent and -independent mechanisms. Blood Coagul Fibrinolysis. 1999;10(4):201-
210. 
52. Chen VM, Hogg PJ. Encryption and decryption of tissue factor. J Thromb Haemost. 
2013;11 Suppl 1:277-284. doi: 10.1111/jth.12228. 
53. Liang HP, Kerschen EJ, Hernandez I, Basu S, Zogg M, Botros F, Jia S, Hessner MJ, 
Griffin JH, Ruf W, Weiler H. EPCR-dependent PAR2 activation by the blood coagulation 
initiation complex regulates LPS-triggered interferon responses in mice. Blood. 
2015;125(18):2845-54. doi: 10.1182/blood-2014-11-610717.  
54. Yuan Q, Zhang D, Wu S, Yu J, Yu L, Sun Y, Du Z, Li Z, Zhou L, Wu X, Hu J. FVIIa 
prevents the progressive hemorrhaging of a brain contusion by protecting microvessels 
via formation of the TF-FVIIa-FXa complex. Neuroscience. 2017;348:114-125. doi: 
10.1016/j.neuroscience.2017.02.020. 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 17 
55. Collier ME, Mah PM, Xiao Y, Maraveyas A, Ettelaie C. Microparticle-associated tissue 
factor is recycled by endothelial cells resulting in enhanced surface tissue factor activity. 
Thromb Haemost. 2013;110(5):966-976. doi:10.1160/TH13-01-0055. 
56. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. 
Endothelial microparticles in diseases. Cell Tissue Res. 2009;335(1):143-151. doi: 
10.1007/s00441-008-0710-9. 
57. Benedict CR, Pakala R, Willerson JT. Endothelial-dependent procoagulant and 
anticoagulant mechanisms. Recent advances in understanding. Tex Heart Inst J. 
1994;21(1):86-90. 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 18 
Figure Legends 
Fig. 1. Increase in endothelial permeability on PAR2 activation. Monolayers of HCAEC (A) 
and HDBEC (B) were prepared by culturing the cells (6×104) in gelatin-coated Transwell 
chambers for 4 days. The monolayers were washed twice with PBS and adapted to serum-
free endothelial medium. Blue dextran was added to a final concentration of 1 µg/ml to the 
upper chamber of each Transwell. Sets of cells were activated with PAR2-AP (20 µM), 
PAR1-AP (20 µM) or VEGF-A (25 ng/ml) added to the upper chambers. The samples were 
incubated at 37°C for up to 60 min. Aliquots of the media (200 µl) were removed from the 
bottom chamber and the absorption measured at 584 nm measured. (n = 4; * = p < 0.05) 
Fig. 2. Increase in endothelial permeability in response to fXa. Monolayers of HCAEC (A) 
and HDBEC (B) were prepared by culturing the cells (6×104) in gelatin-coated Transwell 
chambers for 4 days. The monolayers were washed twice with PBS and adapted to serum-
free endothelial medium. Blue dextran was added to a final concentration of 1 ng/ml to the 
upper chamber of each Transwell. Sets of cells were activated with factor Xa (0-10 nM) 
added to the upper chambers. The samples were incubated at 37°C for up to 60 min. 
Aliquots of the media (200 µl) were removed from the bottom chamber and the absorption 
measured at 584 nm measured. (n = 4; * = p < 0.05) 
Fig. 3. Therapeutic concentrations of Rivaroxaban fully inhibit the activity of fXa. Samples of 
fXa (10 nM) were incubated with Rivaroxaban (0.06 and 0.6 µg/ml) or DMSO vehicle. The 
samples were incubated in the presence of a fXa substrate (0.2 mM) and the fXa protease 
activity evaluated by measuring the absorptions at 405 nm. (n = 3; * = p < 0.05) 
Fig. 4. The increase in endothelial permeability is dependent on fXa protease activity. 
Monolayers of HCAEC (A) and HDBEC (B) were prepared by culturing the cells (6×104) in 
gelatin-coated Transwell chambers for 4 days. The monolayers were washed twice with PBS 
and adapted to serum-free endothelial medium. Blue dextran was added to a final 
concentration of 1 µg/ml to the upper chamber of each Transwell. Sets of cells were 
activated with factor Xa (10 nM) in the presence of Rivaroxaban (0.06 and 0.6 µg/ml) or 
©2020, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
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DMSO vehicle. The samples were incubated at 37°C and the effect of Rivaroxaban was also 
monitored at 60 min (A) and also monitored at 30 min (B). Aliquots of the media (200 µl) 
were removed from the bottom chamber and the absorption measured at 584 nm measured. 
(n = 4; * = p < 0.05) 
Fig. 5. The increase in endothelial permeability is mediated through PAR2 activation. 
Monolayers of HCAEC (A) and HDBEC (B) were prepared by culturing the cells (6×104) in 
gelatin-coated Transwell chambers for 4 days. The monolayers were washed twice with PBS 
and adapted to serum-free endothelial medium in the presence or absence of PAR2 and 
PAR1 blocking antibodies (SAM11 and ATAP2 respectively). Blue dextran was added to a 
final concentration of 1 µg/ml to the upper chamber of each Transwell. Sets of cells were 
activated with factor Xa (10 nM) added to the upper chambers. The samples were incubated 
at 37°C for up to 60 min. Aliquots of the media (200 µl) were removed from the bottom 
chamber and the absorption measured at 584 nm measured. (n = 5; * = p < 0.05) 
Fig. 6. PAR2-mediated increase in endothelial permeability occurs in response to fXa but not 
TF-fVIIa. Monolayers of HCAEC were prepared by culturing the cells (6×104) in gelatin-
coated Transwell chambers for 4 days. The monolayers were washed twice with PBS and 
adapted to serum-free endothelial medium. Blue dextran was added to a final concentration 
of 1 ng/ml to the upper chamber of each Transwell. A) Sets of cells were incubated with 
purified TF-containing microvesicles or with recombinant TF (1 U/ml), in the presence or 
absence of fVIIa (5 nM), and compared to treatment with fXa (10 nM) alone. The samples 
were incubated at 37°C and examined at 60 or 120 min. Aliquots of the media (200 µl) were 
removed from the bottom chamber and the absorption measured at 584 nm measured. (n = 
3; * = p < 0.05). B) Sets of cells were incubated with purified TF-containing microvesicles or 
with recombinant TF (1 U/ml), in the presence of fVIIa (5 nM), and in the presence or 
absence of fXa (10 nM). The samples were incubated at 37°C for up to 60 min. Aliquots of 
the media (200 µl) were removed from the bottom chamber and the absorption measured at 
584 nm measured. (n = 3). 
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